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Summary
Objectives:  Adenoid  cystic  carcinomas  (ACC)  are  rare  malignant  tumours  arising  in  the  major
and minor  salivary  glands.  Involvement  of  the  nasal  cavity  and  paranasal  sinuses  is  rare  and
poorly described.  The  purpose  of  this  study  was  to  deﬁne  the  clinical  and  prognostic  criteria  of
ACC of  the  paranasal  sinuses  based  on  the  review  of  a  series  of  25  cases.
Material  and  methods:  Single-centre  retrospective  study  of  25  cases  of  ACC  of  the  paranasal
sinuses managed  between  1998  and  2011,  evaluating  epidemiological,  clinical,  diagnostic  and
prognostic criteria.  Factors  inﬂuencing  survival  (Kaplan—Meier/Log  Rank  test)  and  the  patient’s
quality of  life  (EORTC  QLQ-C30  questionnaire)  were  also  analysed.
Results: Most  patients  (72%)  had  a  locally-advanced  tumour  (stage  T3  or  T4)  at  diagnosis.
Tumour  sites,  in  decreasing  order  of  frequency,  were  the  maxillary  sinus,  nasal  cavities  and
ethmoid sinus.  The  most  common  presenting  complaints  were  maxillary  pain  or  heaviness,
unilateral  blocked  nose,  and  repeated  epistaxis.  When  the  tumour  was  resectable,  treatment
comprised a  combination  of  surgery  and  adjuvant  radiotherapy.  The  5-year  overall  survival
rate was  63%  and  the  5-year  disease-free  survival  rate  was  43%.  The  TNM  stage  at  diag-
nosis (P  =  0.03),  the  histological  subtype  (P  =  0.023),  the  possibility  of  combined  surgery  and
radiotherapy  (P  =  0.03),  and  local  control  (P  =  0.05)  were  signiﬁcant  factors  of  improved  5-year
overall survival.  Positive  surgical  margins  were  associated  with  a  trend  towards  poorer  5-year
disease-free  survival  (ns).
Conclusions:  ACC  are  rare  malignant  tumours  associated  with  a  poor  prognosis,  characterized
by a  high  recurrence  rate.  Recommended  treatment  is  a  combination  of  surgery  and  adju-
r  povant radiotherapy  wheneve
histological  subtype,  treatment  
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ntroduction
denoid  cystic  carcinomas  (ACC)  are  rare  malignant
umours,  corresponding  to  5%  of  all  paranasal  sinus  malig-
ant  tumours  [1],  which  represents  less  than  0.15%  of  all
alignant  head  and  neck  tumours,  regardless  of  site  and
istology  [2].  ACCs  usually  arise  in  the  major  and  minor  sali-
ary  glands,  but  can  occur  in  all  sites  comprising  secretory
lands  (breast,  cervix,  colon,  prostate).
ACCs  are  tumours  with  slow  and  insidious  growth,  often
iscovered  at  a  late  and  locally  advanced  stage.  Paranasal
inus  tumours  are  associated  with  a  poorer  prognosis  and
urgery  of  these  sites  is  often  complicated  by  the  extent  of
ocal  progression.  Recurrences  are  frequent  and  occur  late,
ometimes  many  years  after  initial  management  [3].
The  purpose  of  this  study  was  to  analyse  the  clinical
nd  prognostic  criteria  of  this  rare  and  poorly  known  entity,
ased  on  the  study  of  25  patients  with  ACC  of  the  paranasal
inuses  in  the  light  of  the  most  recent  knowledge  based  on
 review  of  the  literature.
aterial and methods
his  single-centre  retrospective  study  analysed  all  cases  of
CC  of  the  paranasal  sinuses  and  nasal  cavities  observed
etween  1998  and  2011.  Cases  of  ACC  were  identiﬁed  by
omputerized  coding  (C30.0  and  C.31.0,  1,  2,  3,  9)  of  the
nternational  Classiﬁcation  of  Diseases  (ICD-10,  revised  in
011).  Patients  with  an  ACC  involving  a  site  other  than
he  paranasal  sinuses  and  nasal  cavities  or  with  a  different
istopathology  were  excluded.
The  following  parameters  were  evaluated  for  each
atient:
 tumour  stage  according  to  the  AJCC  2007  TNM  staging  sys-
tem  taking  into  account  the  classiﬁcation  indicated  in  the
patient’s  medical  charts  based  on  physical  examination,
imaging  and  histological  examination  of  the  operative
specimen;
 histological  type  and  subtype  (tubular,  cribriform,  solid
or  mixed)  according  to  the  initial  histology  report  when  it
was  indicated,  or  retrospectively  by  review  of  the  slides;
 presenting  symptoms  and  symptoms  related  to  post-
treatment  sequelae;
 initial  therapeutic  management,  comprising  the  type  of
surgery,  examination  of  surgical  margins,  any  adjuvant
therapy.
Local  recurrence  was  evaluated  by  calculating  the  time
o  onset  following  completion  of  ﬁrst-line  treatment.  When
his  interval  was  less  than  6  months,  the  patient  was  con-
idered  to  present  progressive  disease.  Overall  survival  and
isease-free  survival  probabilities  were  calculated  accord-
ng  to  the  Kaplan—Meier  method;  prognostic  factors  were
nalysed  by  Log  Rank  test  with  a  limit  of  signiﬁcance  of
 <  0.05.
The  validated  standardized  EORTC  QLQ-C30  quality  of  lifeuestionnaire  (qualitative  self-assessment  scale  of  severity)
as  prospectively  sent  to  13  patients  after  having  obtained
heir  agreement  by  telephone.  Only  one  patient  did  not
eturn  the  questionnaire.  The  questionnaire  was  not  sent
c
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o  12  patients  of  the  study  (nine  deceased  patients,  three
atients  lost  to  follow-up).  The  EORTC  QLQ-C30  quality  of
ife  questionnaire  was  used  to  calculate  a  global  quality  of
ife  score:  a  high  score  indicated  a  good  perceived  quality
f  life,  a  functional  score  (Functional  Scale):  a  high  score
ndicated  limited  functional  impairment,  a  general  symp-
om  score  (Symptomatic  Scale):  a  low  score  indicated  few
ymptoms.
Statistical  analysis  was  performed  with  SPSS  20  software.
esults
wenty-ﬁve  patients  with  ACC  of  the  paranasal  sinuses  or
asal  cavities  were  diagnosed  and  managed  between  Jan-
ary  1998  and  December  2011.  This  series  comprised  12
omen  and  13  men  with  a mean  age  at  diagnosis  of  57  ±  14.4
ears.  The  two  most  recent  patients  of  this  series  had
 follow-up  of  9  months  and  12  months,  respectively.  All
atients  underwent  contrast-enhanced  CT-scan  of  the  facial
ones,  neck  and  chest.  MRI  of  the  facial  bones,  which  is
ow  systematically  requested,  was  not  performed  in  seven
atients  (due  to  changing  practices  during  the  course  of  this
etrospective  series).  PET-scan  has  become  systematic  in
ecent  years  as  part  of  the  initial  work-up  and  for  follow-
p  in  the  presence  of  signs  of  progression.  Table  1  presents
he  distribution  of  the  patients  of  the  series  according  to
ge,  tumour  site,  histological  subtype  and  TNM  stage.
The  majority  of  patients  (72%)  had  a locally  advanced,
NM  stage  T3  or  T4  tumour  at  the  time  of  diagnosis.  Five  of
he  eight  patients  with  a  T4  tumour  were  classiﬁed  as  stage
4a  and  three  were  classiﬁed  as  stage  T4b.  Only  ﬁve  patients
ad  a  stage  T2  tumour,  and  no  T1  tumours  were  observed
n  this  series.  The  most  common  tumour  site  was  the  maxil-
ary  sinus  (48%),  followed  by  the  nasal  cavity  (24%),  ethmoid
inus  (16%)  and  sphenoid  sinus  (12%).  Only  one  patient  pre-
ented  lymph  node  invasion  at  diagnosis,  classiﬁed  as  N1.
The  most  common  presenting  symptoms  were  feelings  of
axillary  heaviness,  unilateral  blocked  nose  and  recurrent
pistaxis.  Horner’s  syndrome  and  unilateral  seromucous  oti-
is  were  observed  in  two  of  the  three  patients  with  a  tumour
f  the  sphenoidal  sinus.  Pain  was  the  symptom  most  com-
only  reported  by  patients  (64%)  regardless  of  tumour  site.
The  histological  type  and  subtype  of  ACC  were  reported
n  the  initial  histology  report  for  nine  patients.  Review  of
he  histology  slides  deﬁned  the  precise  histological  subtype
or  another  13  patients.  The  slides  were  not  available  for
eview  for  three  patients  (patients  referred  by  other  cen-
res).  These  22  cases  of  ACC  comprised  seven  cribriform
32%),  eight  mixed  (36%),  two  solid  (9%)  and  ﬁve  tubular
23%)  subtypes.  Cribriform  and  tubular  subtypes  were  often
ssociated  and  were  then  classiﬁed  as  mixed  subtype.
All  patients  with  tumours  considered  to  be  resectable
fter  discussion  in  multidisciplinary  meetings  were  treated
y  a  combination  of  surgery  and  adjuvant  radiotherapy.  This
nitial  surgical  management  concerned  17  patients  (68%);
n  81-year-old  patient  with  poor  performance  status  did  not
eceive  adjuvant  radiotherapy.  The  surgical  procedures  most
ommonly  performed  were  maxillectomy  (n  =  8)  with  vary-
ng  degrees  of  resection  of  the  ethmoid  sinus  or  ﬂoor  of  the
rbit,  followed  by  paranasal  maxillo-ethmoidal  resection
n  = 5),  extended  to  the  skull  base  when  necessary  (n  =  2).
Adenoid  kystic  carcinoma  of  paranasal  sinus  259
Table  1  Distribution  of  the  patients  of  the  series  according  to  age,  tumour  site,  histological  subtype  and  TNM  stage.
n  Gender  Age  Site  Stage  Pain  Histology  Surgery  Adjuvant  radiotherapy  Chemotherapy  Metastases
1  F  81  Nasal  cavity  T2  0  Tubular  1  0  0  0
2 M  79  Maxillary  sinus  T3  1  Mixed  1  1  0  0
3 F  53  Maxillary  sinus  T3  1  Mixed  1  1  0  0
4 M  35  Maxillary  sinus  T4a  1  Solid  0  0  1  0
5 M  52  Sphenoid  sinus  T2  1  Tubular  0  1  1  0
6 M  52  Nasal  cavity  T3  0  Tubular  1  1  0  0
7 M  35  Nasal  cavity  T3  1  Mixed  1  1  0  1
8 F  61  Maxillary  sinus  T3  0  Mixed  1  1  0  0
9 M  54  Ethmoid  sinus T4b  0  Mixed  1  1  0  0
10 M  45  Sphenoid  sinus T4a  1  —  1  1  0  0
11 F  50  Maxillary  sinus  T3  1  Cribriform  0  0  1  1
12 M  40  Ethmoid  sinus  T4b  1  Cribriform  0  1  1  0
13 M  81  Maxillary  sinus  T4b  0  Cribriform  0  1  0  0
14 M  40  Maxillary  sinus  T2  0  Tubular  1  1  0  0
15 M  58  Maxillary  sinus  T3  0  Mixed  1  1  0  0
16 F  65  Nasal  cavity  T3  1  Mixed  1  1  0  0
17 F  70  Nasal  cavity  T2  0  Cribriform  1  1  0  0
18 F  50  Maxillary  sinus  T2  1  Cribriform  1  1  0  0
19 F  75  Ethmoid  sinus  T4a  1  —  0  1  1  0
20 M  78  Maxillary  sinus  T3  0  Mixed  1  1  0  0
21 F  57  Maxillary  sinus  T4aN1  1  —  0  1  1  0
22 F  47  Ethmoid  sinus  T3  1  Tubular  1  1  0  0
23 M  52  Nasal  cavity  T3  1  Cribriform  1  1  0  0
24 F  70  Sphenoid  sinus  T4a  1  Cribriform  0  1  0  0
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Eleven  patients  (i.e.  65%  of  operated  patients)  had  positive
surgical  margins  on  histological  examination  of  the  operative
specimen.
Only  four  patients  (stage  T2)  were  managed  by  exclu-
sive  endoscopic  surgery  and  50%  (n  =  2)  of  them  had  negative
surgical  margins.
Eight  patients  (32%)  were  not  treated  by  primary  surgery,
which  was  contraindicated  because  of  multiple  lung  and
bone  metastases  in  one  case  and  excessive  local  extension
in  seven  cases  (six  stage  T4  tumours)  (intracranial,  body  of
the  sphenoid,  infratemporal  fossa).
Another  patient  of  this  series  with  metastatic  disease
at  diagnosis  was  operated,  as  he  presented  a  solitary  lung
metastasis  that  was  surgically  resected.  The  eight  patients
in  whom  surgery  was  contraindicated  were  treated  by  con-
comitant  chemoradiotherapy  (n  =  4),  exclusive  radiotherapy
(n  =  2)  or  palliative  chemotherapy  (n  =  2).
The  mean  follow-up  was  62.9  months.  Nine  patients  had
died  at  the  time  of  the  study.  The  most  common  seque-
lae  after  treatment  were  crusting  (n  =  10,  40%),  oro-antral
communication  (n  =  6,  24%),  seromucous  otitis  (n  =  3,  12%).
Epiphora  (n  =  3,  12%),  anterior  pituitary  insufﬁciency  (n  =  1),
forehead  radiation  necrosis  (n  =  1)  and  malar  cutaneous  ﬁs-
tula  (n  = 1)  were  also  observed.  One  patient  treated  by
adjuvant  radiotherapy  to  the  sphenoidal  sinus  developed
anterior  pituitary  insufﬁciency.
The  5-year  overall  survival  rate  was  63%  and  the  5-year
disease-free  survival  rate  was  43%  (Fig.  1).  Nine  patients
(36%)  developed  local  recurrence,  with  a  mean  time  to
recurrence  of  4.5  years.  Six  patients  (24%)  presented  pro-
gressive  disease  and  none  of  these  patients  could  be  treated
a
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y  salvage  surgery.  Two  other  patients  developed  lung  and
one  metastases  at  1  year  and  3  years,  respectively;  one
f  the  patients  with  a  solitary  lung  metastasis  underwent
urgical  resection  of  the  metastasis.
The  primary  tumour  site  was  not  a  signiﬁcant  prognostic
actor  inﬂuencing  survival  in  this  study,  but  each  sub-site
omprised  only  a  small  number  of  patients.  Age  was  also  not
 signiﬁcant  factor.  In  contrast,  TNM  stage  at  diagnosis  was
 signiﬁcant  prognostic  factor  (P  =  0.03):  stage  T4  was  asso-
iated  with  signiﬁcantly  lower  survival  than  stage  T2  and  T3
Fig.  2).  In  contrast,  stage  T4b  was  not  a  signiﬁcant  progno-
tic  factor  compared  to  all  other  stages  combined  (P  =  0.9)
nd  was  also  not  a signiﬁcant  prognostic  factor,  in  this  series,
ompared  to  stage  T4a  (P  =  0.19).  No  signiﬁcant  difference  in
-year  overall  survival  (P  =  0.927)  or  5-year  disease-free  sur-
ival  (P  =  0.875)  was  observed  according  to  the  endoscopic
r  open  modalities  of  surgery.
Histological  subtype  was  signiﬁcantly  associated  with
 survival  difference:  solid  ACCs  were  associated  with  a
ower  5-year  overall  survival  compared  to  other  histological
ubtypes  (P  =  0.023)  (Fig.  2).  In  contrast,  no  5-year  sur-
ival  difference  was  observed  between  cribriform,  tubular
nd  mixed  subtypes.  The  possibility  of  combination  surgery
nd  adjuvant  radiotherapy  was  signiﬁcantly  associated  with
mproved  5-year  survival  (P  =  0.03)  compared  to  patients
reated  by  exclusive  radiotherapy  or  concomitant  chemora-
iotherapy  (Fig.  2).  The  presence  of  local  recurrence  was prognostic  factor  (P  = 0.05)  associated  with  poorer  5-year
verall  survival  and  positive  surgical  margins  were  asso-
iated  with  a  trend  towards  lower  5-year  overall  survival
nd  disease-free  survival.  In  this  study,  the  positive  surgical
260  G.  Michel  et  al.
Figure  1  Five-year  survival  curves:  overall  survival  (A)  and  disease-free  survival  (B).
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ith surgery  and  adjuvant  radiotherapy  (C).
argin  rate  was  independent  of  the  type  of  surgery,  tumour
ite  and  histological  subtype.
Analysis  of  the  responses  to  the  EORTC  QLQ-C30  quality  of
ife  questionnaire  allowed  calculation  of  a  global  quality  of
ife  score,  a  functional  score  and  a  general  symptom  score.
he  mean  global  quality  of  life  score  after  treatment  was
3%  (range:  42%  to  83%),  for  a  score  of  the  EORTC  database
eference  population  of  68%.  The  mean  score  on  the  Func-
ional  Scale  was  76%  (range:  58%  to  98%)  for  a  reference
core  of  82%  and  the  mean  score  on  the  general  symptom
cale  was  17%  (range:  0  to  38%)  for  a  reference  score  of
5%.
iscussionCC  of  paranasal  sinuses  are  considered  to  be  poor  prog-
osis  ACC,  characterized  by  the  possibility  of  late  and
requent  local  recurrences  and  poor  survival.  These  data
ere  recently  up-dated  by  the  American  Cancer  Society
c
o
astological  subtype  (B),  and  possibility  of  combination  treatment
tudy  based  on  American  cancer  registries,  comprising  3,026
etrospective  cases  of  head  and  neck  ACC  [4].  In  this  series
f  3,026  patients,  94.89%  of  ACC  involved  the  major  salivary
lands  or  oral  cavity  and  only  4.56%  involved  the  orophar-
nx  and  nasopharynx,  while  the  nasal  cavities  and  paranasal
inuses  were  considered  to  be  the  least  common  and  also
he  most  serious  site  (with  an  excess  relative  risk  of  poor
utcome  of  2.79  in  this  site).  In  this  same  study,  Ellington
t  al.  [4]  described  a  declining  incidence  of  head  and  neck
CC  between  1973  and  2007.
The  mean  age  of  the  patients  of  our  study  was  57.4  years,
imilar  to  the  mean  age  reported  in  the  main  publications
4—6].  According  to  the  meta-analysis  by  Martin-Rodriguez
t  al.  (13  articles,  263  cases),  women  are  affected  slightly
ore  frequently  (56.5%)  than  men,  all  head  and  neck  sites
ombined  [7].
Pain  was  the  most  common  presenting  complaint
bserved  in  this  series  (64%),  as  in  the  literature  (59.8%
ccording  to  Perez  et  al.  [6]).
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The  high  rate  of  late  diagnosis  (72%  of  T3—T4  in  our  study)
is  a  well  known  feature  of  ACC  of  the  paranasal  sinuses,  as
the  majority  of  authors  report  an  advanced  tumour  stage  at
the  time  of  initial  management  [8—10].
The  solid  histological  subtype  has  been  repeatedly
reported  to  be  a  factor  of  poor  prognosis  for  ACC  of  the
paranasal  sinuses,  but  also  of  the  major  salivary  glands  [5,6]
with  a  signiﬁcantly  lower  5-year  survival  than  for  other
histological  subtypes.  Some  studies  have  investigated  the
presence  of  HER-2/Neu  mutations,  classically  observed  in
certain  glandular  tumours  (20%  to  30%  in  breast  cancer):  this
mutation  does  not  appear  to  play  a  role  in  ACC,  but  these
data  are  derived  from  small  series  [5].  In  contrast,  recent
studies  based  on  almost  200  cases  of  ACC  have  shown  that
expression  of  c-Kit  mutations  would  be  associated  with  a
signiﬁcantly  poorer  prognosis,  while  EGFR  expression  was
associated  with  a  signiﬁcantly  better  3-year  survival  [11].
Canadian  histological  studies  have  demonstrated  overex-
pression  of  the  c-Kit  mutation  in  tubular  and  solid  subtypes
of  ACC,  which  also  classically  correspond  to  forms  associated
with  a  poorer  prognosis.  In  addition  to  being  a  factor  of  poor
prognosis,  signiﬁcantly  correlated  with  the  solid  histological
subtype,  the  presence  of  c-Kit  mutations  may  also  be  useful
to  distinguish  true  ACC  from  adenocarcinomas  with  a  similar
morphological  appearance  [12].
The  majority  of  authors  describe  a  combination  of  pri-
mary  surgery  followed  by  adjuvant  radiotherapy  as  the
recommended  reference  treatment.  However,  the  beneﬁt
of  adjuvant  radiotherapy  has  never  been  clearly  demon-
strated  in  the  absence  of  a  randomized  prospective  trial
[10,13,14].  Proton  therapy  appears  to  provide  better  local
control,  particularly  in  the  presence  of  deep  extension
(sphenoid,  clivus)  [15].  The  absence  of  primary  surgery  is
signiﬁcantly  associated  with  an  increased  relative  risk  of
recurrence  (excess  relative  risk  of  2.22)  [4]. No  survival  dif-
ference  was  observed  in  the  present  study  as  a  function
of  the  type  of  surgery  performed,  either  between  the  var-
ious  open  approaches,  or  by  comparing  open  surgery  and
endoscopic  surgery.  These  results  must  be  interpreted  in
the  light  of  the  small  number  of  patients  managed  by  endo-
scopic  surgery.  On  the  other  hand,  the  quality  of  resection
appears  to  be  primordial,  regardless  of  the  surgical  tech-
nique  used.  Positive  surgical  margins  were  associated  with
a  trend  towards  lower  5-year  overall  survival  and  5-year
disease-free  survival,  which  is  consistent  with  the  data  of
the  literature  for  head  and  neck  ACC.  Dubergé  et  al.  [16],
based  on  the  study  of  169  cases  of  head  and  neck  ACC,
demonstrated  a  markedly  favourable  impact  of  negative
surgical  margins  on  disease-free  survival  and  local  disease-
free  survival.  The  positive  surgical  margin  rate  was  slightly
lower  than  that  reported  in  our  study  (53%  versus  65%),  but
concerned  all  head  and  neck  sites,  particularly  the  major
salivary  glands,  for  which  large  resection  is  considered  to
be  easier.  The  place  of  neoadjuvant  chemotherapy,  based
exclusively  on  retrospective  studies,  has  not  been  validated
[7,17].  The  place  of  chemotherapy  in  the  palliative  setting
was  fairly  clearly  deﬁned  by  Laurie  et  al.  in  a  study  pub-
lished  in  Lancet  Oncology  and  based  on  a  review  of  the
literature  (34  studies,  441  patients).  This  meta-analysis  indi-
cated  that  a  favourable  result  could  be  expected  for  a  small
proportion  of  patients,  particularly  those  with  progressive
and  symptomatic  disease;  many  patients  present  slow  and
p
p
c
c261
ell  tolerated  metastatic  progression  and  do  not  derive  any
eneﬁt  from  systematic  chemotherapy,  which  should  there-
ore  not  be  proposed  [18].  When  palliative  chemotherapy
s  indicated,  mitoxantrone  or  vinorelbine  are  two  reason-
ble  ﬁrst-line  options.  These  molecules,  evaluated  in  clinical
rials,  provided  objective  responses  with  an  acceptable  tox-
city  proﬁle.  An  anthracycline  such  as  epirubicin  also  appears
o  be  a  reasonable  option  [19,20].  Paclitaxel  and  cisplatin
re  not  recommended  due  to  their  demonstrated  lack  of
fﬁcacy  and  their  toxicity.
Survival  ﬁgures  are  based  on  retrospective  data  from  case
eries  (level  of  proof  D).  Five-,  10-  and  15-year  overall  sur-
ival  is  90.34%,  79.88%  and  69.22%,  respectively,  according
o  American  cancer  registry  data  based  on  more  than  3000
atients,  all  sites  combined  [4].  In  contrast,  the  5-year  sur-
ival  rate  in  our  study  was  63%,  highlighting  the  marked
urvival  difference  according  to  tumour  site.  These  results
ust  be  interpreted  in  the  light  of  the  limited  follow-up  for
he  most  recent  patients  (9  and  12  months  respectively  for
he  last  two  patients  included).  In  a  study  of  more  than  100
ases  of  head  and  neck  ACC,  Optalec  et  al.  [21]  reported  a
igher  survival  rate  for  primary  tumours  of  the  major  sali-
ary  glands  compared  to  other  sites.  Few  series  exclusively
evoted  to  ACC  of  the  paranasal  sinuses  have  been  pub-
ished  in  the  literature.  Liu  WS  et  al.  [22]  reported  a  series
f  80  patients  in  Beijing  with  ACC  of  the  maxillary  sinus:
he  5-year  overall  survival  rate  was  65.2%,  very  similar  to
hat  observed  in  our  study.  Ten-year  and  15-year  overall
urvival  rates  were  only  37.1%  and  26.3%,  respectively.  Sim-
lar  survival  ﬁgures  were  reported  by  Wiseman  et  al.  [8]  in
atients  with  ACC  of  the  paranasal  sinuses,  with  5-year,  10-
ear  and  15-year  overall  survival  rates  of  65%,  55%  and  28%,
espectively,  conﬁrming  the  slow  and  insidious  course  of
CC,  justifying  particularly  prolonged  follow-up  of  tumours
f  this  site.
The  metastasis  rate  in  the  present  series  was  low:  only
wo  patients  (8%)  developed  metastasis.  Metastasis  rates
ary  considerably  in  the  literature  and  the  main  metastatic
ites  are  lung  and  bone.  In  the  American  Cancer  Society
tudy  by  Ellington  et  al.  [4], concerning  all  sites  of  head  and
eck  ACC,  11.57%  of  patients  presented  metastases.  In  the
tudy  by  Sung  et  al.  [23],  based  on  94  patients  with  head  and
eck  ACC,  48%  presented  metastatic  progression.  ACC  of  the
aranasal  sinuses  have  also  been  reported  to  be  associated
ith  lower  metastasis  rates  than  ACC  of  the  major  salivary
lands.  These  results  are  consistent  with  the  metastasis  rate
eported  in  our  study,  suggesting  that,  although  ACC  of  the
aranasal  sinuses  is  associated  with  a  poorer  prognosis,  the
isk  of  metastasis  is  lower  than  for  other  head  and  neck  sites.
Wei  et  al.  [24]  and  Zhang  et  al.  [25],  in  two  articles  pub-
ished  in  Chinese,  based  on  two  series  of  40  patients  and
0  patients  with  ACC  of  the  nasal  cavities  and  paranasal
inuses,  reported  5-year  overall  survival  rates  of  76.9%  and
4%,  respectively.  The  survival  rate  of  the  ﬁrst  study  was
igher  than  that  usually  reported  in  other  published  stud-
es,  but  concerned  a  population  predominantly  composed
f  patients  with  ACC  of  the  maxillary  sinus  (80%  versus  less
han  50%  in  the  other  series),  which  may  indicate  a  better
rognosis  for  this  speciﬁc  site.  As  these  studies  did  not  com-
rise  statistical  analysis  to  identify  prognostic  factors,  other
onfounding  factors,  particularly  treatment-related  factors,
annot  be  excluded.
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Analysis  of  the  global  quality  of  life  of  patients  man-
ged  for  ACC  of  the  paranasal  sinuses  was  similar  to  that  of
he  EORTC  reference  population.  The  score  on  the  general
ymptom  scale  was  also  very  similar  to  that  of  the  refer-
nce  population.  In  contrast,  the  much  lower  scores  on  the
unctioning  scale  in  our  study  compared  to  the  general  pop-
lation  reﬂects  the  markedly  negative  impact  on  the  daily
ife  of  surviving  patients.
onclusion
CC  are  malignant  tumours  with  a  poor  prognosis.  Paranasal
inus  tumours  are  rare  compared  to  other  head  and  neck
ites,  particularly  the  major  salivary  glands,  and  are  asso-
iated  with  a  poorer  prognosis.  They  are  characterized  by
 high  rate  of  recurrences  that  can  occur  many  years  after
rimary  treatment.  In  contrast,  the  metastasis  rate  appears
o  be  lower  than  that  observed  for  salivary  gland  tumours.
The  recommended  treatment,  whenever  possible,  is
ased  on  a  combination  of  surgery  and  adjuvant  radiothe-
apy.  The  5-year  overall  survival  varies  as  a  function  of  TNM
tage,  histological  subtype,  treatment  modalities  and  local
ontrol.  The  solid  histological  subtype  appears  to  be  asso-
iated  with  the  poorest  prognosis  and  could  be  correlated
ith  overexpression  of  the  c-Kit  mutation.  Chemotherapy
hould  be  reserved  for  the  palliative  setting,  preferably  in
atients  with  symptomatic,  progressive  disease.
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